

## UNITED STATES PATENT AND TRADEMARK OFFICE

## UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

27737 e 06/11/2007 ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO, CA 92121

Paper No.

Application No.:	10/561,101	Date Mailed:	06/11/2007
First Named Inventor:	Smith, Brian,	Examiner:	,
Attorney Docket No.:	68.US2.PCT	Art Unit:	1614
Confirmation No.:	2470	Filing Date:	05/26/2006

Please find attached an Office communication concerning this application or proceeding.

## 

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

The amendment document filed on <u>16 December</u>, <u>2005</u> is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121 or 1.4. In order for the amendment document to be compliant, correction of the following item(s) is required.

item(s) is req		source to be compliant, conceasing of the following
□ 1. A	WING MARKED (X) ITEM(S) CAUSE THE AMENDME mendments to the specification:  1. A. Amended paragraph(s) do not include markings.  1. New paragraph(s) should not be underlined.  1. C. Other	NT DOCUMENT TO BE NON-COMPLIANT:
2. A	bstract:  A. Not presented on a separate sheet. 37 CFR 1.72.  B. Other	
	mendments to the drawings:  A. The drawings are not properly identified in the top "Annotated Sheet" as required by 37 CFR 1.121(c)  B. The practice of submitting proposed drawing correshowing amended figures, without markings, in co. Cother	l). ection has been eliminated. Replacement drawings
	mendments to the claims:  A. A complete listing of all of the claims is not presen B. The listing of claims does not include the text of al C. Each claim has not been provided with the proper of each claim cannot be identified. Note: the stat number by using one of the following status identi (Previously presented), (New), (Not entered), (Wil D. The claims of this amendment paper have not bee	I pending claims (including withdrawn claims) status identifier, and as such, the individual status us of every claim must be indicated after its claim fiers: (Original), (Currently amended), (Canceled), hdrawn) and (Withdrawn-currently amended).
	other (e.g., the amendment is unsigned or not signed in mendment format required by 37 CFR 1.121, see MPE	
<ol> <li>Applicant filed after</li> </ol>	DS FOR FILING A REPLY TO THIS NOTICE: t is given no new time period if the non-compliant amr r allowance, or a drawing submission (only) if applican ent with corrections, the entire corrected amendment	t wishes to resubmit the non-compliant after-final
correction (including amendm Quayle a	t is given one month, or thirty (30) days, whichever is I n, if the non-compliant amendment is one of the followi g a submission for a request for continued examination ent filed within a suspension period under 37 CFR 1.1c ction. If any of above boxes 1 to 4 are checked, the co pliant amendment in compliance with 37 CFR 1.121.	ng: a preliminary amendment, a non-final amendmen (RCE) under 37 CFR 1.114), a supplemental 3(a) or (c), and an amendment filed in response to a
ameno <u>Failur</u> Ab file No	sions of time are available under 37 CFR 1.136(a) on dment or an amendment filed in response to a Quayle a e to timely respond to this notice will result in: andonment of the application if the non-compliant ame d in response to a Quayle action; or n-entry of the amendment if the non-compliant amend endment.	action. endment is a non-final amendment or an amendment
	nents Examiner (LIE), if applicable Margaret Byars	Telephone No: 5712726581